Valsartan And Hydrochlorothiazide
Product Images NDC 50090-1763

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 50090-1763). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (Lbl500901762)

Label Image (Lbl500901762)
The text appears to be partially readable and partially gibberish. The readable part of the text suggests that the item being described should be stored at a temperature between 68 and 77 degrees Fahrenheit and mentions "9 tasters." However, the rest of the text appears to be non-English characters and gibberish. Therefore, it is not possible to generate a useful description based on this result.*
FDA Label Image

Lbl500901763

Lbl500901763
FDA Label Image

Figure 1: Probability Of Achieving Systolic Blood Pressure <140 Mmhg At Week 8 (Valhyctz Fig1)

Figure 1: Probability Of Achieving Systolic Blood Pressure <140 Mmhg At Week 8 (Valhyctz Fig1)
The text describes a medical study evaluating the effectiveness of the medication Valsartan and Hydrochlorothiazide in reducing systolic blood pressure. The study tracked baseline blood pressure levels of participants and measured the probability of achieving a systolic blood pressure of less than 140 mmHg at week 8 using a graph. Details about the medication dosages are also provided.*
FDA Label Image

Figure 2: Probability Of Achieving Diastolic Blood Pressure <90 Mmhg At Week 8 (Valhyctz Fig2)

Figure 2: Probability Of Achieving Diastolic Blood Pressure <90 Mmhg At Week 8 (Valhyctz Fig2)
The text describes a figure showing the probability of achieving a diastolic blood pressure (DBP) of less than 90 mmHg at week 8. The figure displays a baseline DBP and measurements of 100, 95, and 105 mmHg.*
FDA Label Image

Figure 3: Probability Of Achieving Systolic Blood Pressure <130 Mmhg At Week 8 (Valhyctz Fig3)

Figure 3: Probability Of Achieving Systolic Blood Pressure <130 Mmhg At Week 8 (Valhyctz Fig3)
The text describes a figure showing the probability of achieving a systolic blood pressure of less than 130 mmHg at Week 8 using Valsartan and Hydrochlorothiazide medication. The figure displays the baseline SBP readings between 140 to 180 mmHg. There are three types of medication compared in the figure- Valsartan and Hydrochlorothiazide at doses 320mg/25mg and 284mg and a Placebo.*
FDA Label Image

Figure 4: Probability Of Achieving Diastolic Blood Pressure <80 Mmhg At Week 8 (Valhyctz Fig4)

Figure 4: Probability Of Achieving Diastolic Blood Pressure <80 Mmhg At Week 8 (Valhyctz Fig4)
This is a graph that shows the probability of achieving diastolic blood pressure below 80mmHg after 8 weeks of treatment with Valsartan and Hydrochlorothiazide, compared to a placebo, in patients with a baseline blood pressure above 95-110 mmHg. The dosage of Valsartan is 320mg and Hydrochlorothiazide is 25mg.*
FDA Label Image

Chemical Structure1 (Valhyctz Str1)

Chemical Structure1 (Valhyctz Str1)
FDA Label Image

Chemical Structure 2 (Valhyctz Str2)

Chemical Structure 2 (Valhyctz Str2)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.